All In Biotech

Drug Trial Radar · NCT05781048

A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

An Open-label, Multi-center Phase I Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Actual

Start

Mar 23, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HRS-6209Drug

    HRS-6209

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety endpoints: Number of subjects with adverse events and the severity of adverse eventsTime frame: every 4 weeks after treatment initiation,up to approximately 2 years.
  2. DLT(Dose-limiting toxicity)Time frame: during the first 30-day cycle of SHR-6209 treatment
  3. MTD(Maximum tolerated dose)Time frame: 4 weeks after treatment initiation
  4. RP2D(Recommended Phase II Dose)Time frame: 4 weeks after treatment initiation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center-

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.